A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis. [electronic resource]
Producer: 20170901Description: 393-402 p. digitalISSN:- 1476-5551
- Adult
- Aged
- Aged, 80 and over
- Alleles
- Antineoplastic Agents -- pharmacology
- Biomarkers
- Bone Marrow -- pathology
- Female
- Follow-Up Studies
- Humans
- Janus Kinase 2 -- antagonists & inhibitors
- Male
- Middle Aged
- Molecular Targeted Therapy
- Neoplasm Grading
- Phenotype
- Primary Myelofibrosis -- diagnosis
- Protein Kinase Inhibitors -- pharmacology
- Retreatment
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.